There is insufficient publicly available evidence at the current time to accurately verify this claim.
The article published by the ScienceDirect states that the spike glycoprotein of SARS-CoV-2 is the mixture of bat SARS-CoV and a not known Beta-CoV and it also uses the same ACE2 cell receptor and mechanism for the entry to host cell which is previously used by the SARS-CoV. It further added the single N501T mutation in SARS-CoV-2’s Spike protein may have significantly enhanced its binding affinity for ACE2 and despite all these in-vetro evidence, there is still no confirming evidence of these compounds in the clinical COVID-19 patients.
Even though there are rumours and theories of a third receptor protein binding in the SARS-CoV-2 virus, there is no clinical evidence available as on 22 April 2020 to prove the existence of third binding mode related to coronavirus.
The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19 including symptoms, prevention and available treatment, please refer to the World Health Organisation or your national healthcare authority.